TRIM13 is a membrane-anchored E3 ubiquitin ligase that regulates multiple cellular processes through targeted protein degradation. The protein functions primarily in ER-associated degradation (ERAD) pathways and exhibits complex roles in disease pathogenesis 1. In cancer contexts, TRIM13 demonstrates tumor suppressive properties by inhibiting cell proliferation and inducing autophagy through p62 ubiquitination and KEAP1/NRF2 pathway regulation in lung adenocarcinoma 2. However, TRIM13's role varies by disease context - it promotes atherosclerosis by degrading liver X receptors and SOCS proteins, leading to impaired cholesterol efflux and foam cell formation 3. In inflammatory responses, TRIM13 acts as a negative regulator by ubiquitinating TRAF6, thereby dampening neuroinflammation induced by methamphetamine and HIV-1 Tat proteins 4. The protein also modulates innate immunity by targeting MAVS for autophagic degradation in avian species 5. TRIM13 expression is dysregulated in various conditions, including decreased levels in COPD where it normally protects against ER stress-induced epithelial cell damage 6, and altered levels serving as potential biomarkers in Machado-Joseph disease 7. These findings establish TRIM13 as a context-dependent regulator with significant therapeutic potential across multiple disease states.